References
- Aljiffry M, Walsh M J, Molinari M (2009). Advance in diagnosis,treatment and palliation of cholangiocarcarcinoma: 1990-2009. World J Gastrointestinal, 15, 4240-62. https://doi.org/10.3748/wjg.15.4240
- Chen YK, Huang AH, Cheng PH, et a1(2012). Overexpression of Smad proteins, especially Smad7, in oral epithelial dysplasias. Clin Oral Investig, 6, 6.
- Dahler AL, Cavanagh LL, Saunders NA (2001). Suppression of keratinocyte growth and differentiation by transforming growth factor beta1 involves multiple signaling pathways. J Invest Dermatol, 116, 266-74. https://doi.org/10.1046/j.1523-1747.2001.01243.x
-
Drabsch Y, Ten Dijke P (2012). TGF-
${\beta}$ signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev, 7, 20. - Gratchev A, Kzhyshkowska J, Kannookadan S, et a1 (2008). Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoidmediated surface expression of TGF-beta receptor II. J Immunol, 180, 6553-65. https://doi.org/10.4049/jimmunol.180.10.6553
- Halder SK, Rachakonda G, Deane NG, et a1 (2008). Smad7 induces hepatic metastasis in colorectal cancer. Brit J Cancer, 4, 957-65.
- Hayashi H, Abollah S, Qiu Y, et al (1997). The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell, 89, 1165-73. https://doi.org/10.1016/S0092-8674(00)80303-7
- Iiizumi M, Liu W, Pai SK, et al (2008). Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta, 1786, 87-104.
- Iwatsuki M, Mimori K, Yokobori T, et al (2010). Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci, 101, 293-9. https://doi.org/10.1111/j.1349-7006.2009.01419.x
- Kalluri R, Weinberg RA(2009). The basics of epithelial-mesenchymal transition. J Clin Invest, 119, 1420-8. https://doi.org/10.1172/JCI39104
- Kim YH, Lee HS, Lee HJ, et a1 (2004). Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol, 15, 574-80. https://doi.org/10.1093/annonc/mdh131
- Kleeff J, Ishiwata T, Maruyama H , et al(1999). The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 18, 5363-72. https://doi.org/10.1038/sj.onc.1202909
- Kokkinos MA, wafai R, Wong MK, et al (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tiss Organs, 185, 191-203. https://doi.org/10.1159/000101320
-
Lan HY, Chung AC (2011). Transforming growth factor-
${\beta}$ and Smads. Contrib Nephrol, 170, 75-82. https://doi.org/10.1159/000324949 - Leng A, Liu T, He Y, Li Q, Zhang G (2009). Smad4/Smad7 balance: A role of tumorigenesis in gastric cancer. Exp Mol Pathol, 87, 48-53. https://doi.org/10.1016/j.yexmp.2009.03.003
- Li H, Qin Y, Cui Y, et al (2011). Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg, 28, 226-31. https://doi.org/10.1159/000327361
- Li Y, Wang JP, Santen RJ, et al (2010). Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology, 151, 5146-56. https://doi.org/10.1210/en.2009-1506
-
Liu Q, Zhang Y, Mao H, et a1 (2012). A crosstalk between the Smad and JNK signaling in the TGF-
${\beta}$ -induced epithelialmesenchymal transition in rat peritoneal mesothelial cells. PLoS One, 7, e32009. https://doi.org/10.1371/journal.pone.0032009 - Moustakas A, Heldin CH (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci, 98, 1512-20. https://doi.org/10.1111/j.1349-7006.2007.00550.x
- Nakajima S, Doi R, Toyoda E, et al (2004). N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res, l0, 4125-33.
- Neilson EG (2006). Mechanisms of disease: Fibroblasts-a new look at an old problem. Nat Clin Pract Nephrol, 2, 101-8. https://doi.org/10.1038/ncpneph0093
- Park YN, Chae KJ, Oh B K, et al (2004). Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism transforming growth factor-beta. Hepatogastroenterology, 51, 396-400.
- Peinado H, Olmeda D, Cano A (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer, 7, 415-28. https://doi.org/10.1038/nrc2131
- Pittman AM, Naranjo S, Webb E, et al(2009). The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res, 19, 987-93. https://doi.org/10.1101/gr.092668.109
- Polette M, Mestdagt M, Bindels S, et al (2007). Beta-catenin and ZO-1: shuttle molecules involved in tumor invasionassociated epithelial-mesenchymal transition processes[J]. Cells Tiss Organs, 185, 61-5. https://doi.org/10.1159/000101304
-
Sabe H (2011). Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor
${\beta}$ signalling. J Biochem, 149, 633-9. https://doi.org/10.1093/jb/mvr044 - Sandusky G, Berg DT, Richardson MA, et al (2002). Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads[J]. J Biol Chem, 277, 49815-9. https://doi.org/10.1074/jbc.C200543200
- Sethi S, Sarkar FH, Ahmed Q, et al (2011). Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol, 4, 222-6. https://doi.org/10.1593/tlo.10244
- Yu H, Zhao G, Li H, et al (2012). Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Gene, 1, 3.
- Zhu HJ, Iaria J, Sizeland AM(1999). Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem, 274, 32258-64. https://doi.org/10.1074/jbc.274.45.32258
- Zhu L, Wang L, Wang X, et al (2011). Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS One, 6, e17415. https://doi.org/10.1371/journal.pone.0017415
Cited by
- Novel diagnostic and prognostic biomarkers in biliary tract cancer vol.7, pp.5, 2013, https://doi.org/10.1517/17530059.2013.826646
- Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis vol.21, pp.2, 2014, https://doi.org/10.1245/s10434-013-3286-x
- Molecular diagnosis of intrahepatic cholangiocarcinoma vol.22, pp.2, 2014, https://doi.org/10.1002/jhbp.156
- Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer vol.35, pp.7, 2014, https://doi.org/10.1007/s13277-014-1962-5
- SMAD7: a timer of tumor progression targeting TGF-β signaling vol.35, pp.9, 2014, https://doi.org/10.1007/s13277-014-2203-7
- Integrative Analysis of Transcriptional Regulatory Network and Copy Number Variation in Intrahepatic Cholangiocarcinoma vol.9, pp.6, 2014, https://doi.org/10.1371/journal.pone.0098653
- Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.201
- MicroRNA-182 targets SMAD7 to potentiate TGFβ-induced epithelial-mesenchymal transition and metastasis of cancer cells vol.7, pp.2041-1723, 2016, https://doi.org/10.1038/ncomms13884
- GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through the TGF-β1/Smad2 signalling pathway vol.22, pp.3, 2018, https://doi.org/10.1111/jcmm.13442